Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$550000.0.

  • Fate Therapeutics' Change in Accured Expenses fell 12939.6% to -$550000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 11945.83%. This contributed to the annual value of -$1.7 million for FY2024, which is 9426.05% up from last year.
  • Fate Therapeutics' Change in Accured Expenses amounted to -$550000.0 in Q3 2025, which was down 12939.6% from $484000.0 recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Change in Accured Expenses ranged from a high of $10.3 million in Q3 2022 and a low of -$20.4 million during Q1 2023
  • For the 5-year period, Fate Therapeutics' Change in Accured Expenses averaged around -$1.1 million, with its median value being $320000.0 (2024).
  • Examining YoY changes over the last 5 years, Fate Therapeutics' Change in Accured Expenses showed a top increase of 30940.89% in 2021 and a maximum decrease of 106828.36% in 2021.
  • Quarter analysis of 5 years shows Fate Therapeutics' Change in Accured Expenses stood at -$10.4 million in 2021, then surged by 132.63% to $3.4 million in 2022, then crashed by 155.89% to -$1.9 million in 2023, then skyrocketed by 134.6% to $655000.0 in 2024, then plummeted by 183.97% to -$550000.0 in 2025.
  • Its Change in Accured Expenses was -$550000.0 in Q3 2025, compared to $484000.0 in Q2 2025 and -$9.8 million in Q1 2025.